"Epothilones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).
Descriptor ID |
D034261
|
MeSH Number(s) |
D02.540.576.500.984
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Epothilones".
Below are MeSH descriptors whose meaning is more specific than "Epothilones".
This graph shows the total number of publications written about "Epothilones" by people in this website by year, and whether "Epothilones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2011 | 0 | 1 | 1 |
2014 | 1 | 0 | 1 |
2018 | 0 | 1 | 1 |
2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epothilones" by people in Profiles.
-
Selective and Marked Blockade of Endothelial Sprouting Behavior Using Paclitaxel and Related Pharmacologic Agents. Am J Pathol. 2021 12; 191(12):2245-2264.
-
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.
-
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018 08; 150(2):274-281.
-
A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):44-8.
-
Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Br J Cancer. 2012 Jan 03; 106(1):70-6.